Faraci W S, Zorn S H, Sanner M A, Fliri A
Central Research Division, Pfizer Central Research, Groton, CT 06340, USA.
Curr Opin Chem Biol. 1998 Aug;2(4):535-40. doi: 10.1016/s1367-5931(98)80131-2.
The identification of a novel dopamine receptor subtype, referred to as the D4 receptor, which binds the atypical antipsychotic drug clozapine with high potency, has led to the initiation of a drug discovery program that aims to find novel inhibitors of this receptor subtype. A selective screening strategy was utilized, in which 4500 compounds chosen on the basis of structural similarities to known biogenic amine receptor antagonists were tested against both the D4 and D2 dopamine receptor subtypes. A potent D4-selective compound was discovered.
一种新型多巴胺受体亚型(称为D4受体)的鉴定引发了一项药物研发计划,该受体与非典型抗精神病药物氯氮平具有高亲和力。这一发现促使人们寻找针对该受体亚型的新型抑制剂。研究采用了选择性筛选策略,基于与已知生物胺受体拮抗剂的结构相似性,选择了4500种化合物,分别针对D4和D2多巴胺受体亚型进行测试。结果发现了一种强效的D4选择性化合物。